The implementation of GnRH antagonists such as relugolix in treating prostate cancer has shown promising preliminary results in mitigating cardiovascular risk in comparison to GnRH and GnRH agonists [74,75]. This evidence concerns the gene GNRH1 and prostate carcinoma.